Related Experiment Videos
The atherogenic risk of antihypertensive therapy
1Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.
Insights
Antihypertensive drugs successfully lower blood pressure but may cause adverse metabolic changes. These changes can potentially counteract the cardiovascular benefits of blood pressure control.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Antihypertensive therapy has significantly reduced cardiovascular and cerebrovascular disease morbidity and mortality over the past two decades.
- Despite widespread success, certain antihypertensive agents may adversely impact cardiovascular disease development and progression.
- Reductions in cerebrovascular events and heart failure have not been matched by similar decreases in cardiac morbidity or mortality.
Purpose of the Study:
- To investigate the potential adverse effects of specific antihypertensive agents on cardiovascular health.
- To explore the link between antihypertensive drugs and negative metabolic alterations.
- To understand how metabolic changes induced by medications might affect overall cardiovascular outcomes.
Main Methods:
- Review of evidence on antihypertensive therapy outcomes.
- Analysis of studies investigating drug-induced metabolic changes.
- Correlation of metabolic side effects with cardiovascular event rates.
Main Results:
- Evidence suggests certain antihypertensive drugs induce adverse metabolic changes.
- These metabolic alterations may offset or reverse the benefits of blood pressure reduction.
- A discrepancy exists between reduced cerebrovascular events and unchanged cardiac morbidity/mortality.
Conclusions:
- The efficacy of antihypertensive therapy in reducing overall cardiovascular and cerebrovascular disease is well-established.
- However, specific drug classes may induce metabolic disturbances that negatively impact cardiovascular health.
- Further research is needed to identify and mitigate these adverse effects to optimize patient outcomes.
Abstract:
The past 20 years have demonstrated the unqualified success of antihypertensive therapy in reducing morbidity and mortality from cardiovascular and cerebrovascular disease. Evidence mounts, however, that certain antihypertensive agents may, themselves, have an adverse effect on the development and progression of cardiovascular disease. The dramatic reductions in the incidence of cerebrovascular events and congestive heart failure among patients receiving antihypertensive therapy have not been paralleled by similar reductions in cardiac morbidity or mortality. Several lines of evidence now point to the possibility that adverse metabolic changes are induced by certain antihypertensive drugs. These changes may offset, negate, or even reverse the potential benefit afforded by successful blood pressure control.